TABLE 3.
Adverse events during VRC therapy in 24 patients
| Type of event | No. of children with dose of: |
No. of adults with dose of 4 mg/kg (n = 12) |
||||
|---|---|---|---|---|---|---|
| 7 mg/kg (n = 9) |
5 mg/kg (n = 3) |
|||||
| 1-2a | 3-4 | 1-2 | 3-4 | 1-2 | 3-4 | |
| Visual | 1 | 1 | 3 | 1 | ||
| Digestive tract | ||||||
| Diarrhea | 3 | 1 | 8 | 1 | ||
| Vomiting | 7 | 2 | 5 | 2 | ||
| Nausea | 3 | 1 | 7 | 2 | ||
| Neurologic | ||||||
| Headache | 2 | 3 | 3 | |||
| Confusion | 1 | 1 | ||||
| Hepatic | ||||||
| AST level ≥2.5 times ULN | 3 | 2 | 1 | 2 | 1 | |
| ALT level ≥2.5 times ULN | 3 | 2 | 1 | 1 | 4 | |
| γ-GT level ≥2.5 times ULN | 3 | 1 | 1 | 7 | 2 | |
| ALP level ≥2.5 times ULN | 2 | |||||
| Bilirubin level ≥1.5 times ULN | 3 | |||||
a
Severity levels: 1, mild; 2, moderate; 3, severe; 4, life threatening.